TerminatedInterventionalPhase 3Updated Oct 17, 2014
Efficacy and Safety of Tacrolimus Sustained-release Capsules in Induction Phase Treatment in Lupus Nephritis | NCT01288664 | Trialant
WithdrawnInterventionalPhase 3Updated Feb 12, 2014
Efficacy and Safety of Tacrolimus Sustained-release Capsules in Induction Phase Treatment in Lupus Nephritis
ClinicalTrials.gov ID
NCT01288664
Lead Sponsor
Sun Yat-sen UniversityOTHER
Overall Status
Withdrawn
Study Type
Interventional
Phase
Phase 3
Enrollment
0Actual
Last Update Posted
Feb 12, 2014Estimated
Start Date
Jan 2011
Primary Completion Date
Dec 2012Estimated
Completion Date
Dec 2012Estimated
Brief Summary
This is a pilot study to evaluate the efficacy and safety of Tacrolimus Sustained-release Capsules (ADVAGRAF) for the induction therapy of Lupus Nephritis (LN) (V, III +V, IV+V).
Lupus Nephritis
ADVAGRAF
Ages Eligible for Study
Child (0-17)Adult (18-64)Older Adult (65+)
Sexes Eligible for Study
All
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Subjects of either sex, 14-65 years of age;
Diagnosis of systemic lupus erythematosus (SLE) according to the albumin-creatinine ratio (ACR) criteria (1997);
Kidney biopsy within the 6 months prior to study with a histologic diagnosis (ISN/RPS 2003 classification of LN) class V, III +V, IV+V;
LN (Class IV+V): proteinuria > 1g/24hr or Scr > 1.3 mg/dl or active urinary sediment (erythrocyte cast, > 5 white blood cell count (WBC) /high power field (hpf)(excluding infection ), > 5 red blood cell count (RBC)/hpf;
LN (Class V or III +V ): proteinuria > 2g/24hr or Scr > 1.3 mg/dl;
Provision of written informed consent by subject or guardian
Exclusion Criteria:
Inability or unwillingness to provide written informed consent
Usage of immunosuppression therapy (MMF, Cyclophosphamide (CTX), Cyclosporine A (CysA), methotrexate (MTX) ect) for more than 1 week within 1 month or Pulse intravenous MP treatment prior to recruitment
Scr > 4mg/dl (354umol/L)
Needing pulse intravenous Methylprednisolone (MP) or intravenous immunoglobulin
History of significant gastrointestinal disorders (e.g. severe chronic diarrhea or active peptic ulcer disease) within 3 month prior to enter this study
Any Active systemic infection or history of serious infection within one month of entry
known infection with HIV, hepatitis B, or hepatitis C
Known hypersensitivity or contraindication to tacrolimus, corticosteroids
Participation in another clinic trial and/or receipt of investigational drugs within 4 weeks prior to screening
Pregnancy, nursing or use of a non-reliable method of contraception.
Primary Purpose
Treatment
Allocation
Non-Randomized
Interventional Model
Single Group Assignment
Masking
None (Open Label)
No central contacts
There are no central contacts for this study.
The First Affiliated Hospital of Sun Yat-sen University